Genetic polymorphism of CYP2U1, a cytochrome P450 involved in fatty acids hydroxylation

References 

1. Nebert DW, Russell DW. Clinical importance of the cytochrome P450. Lancet. 2002;360:1155–1162
   • Abstract
   • Full Text
   • Full-Text PDF (125 KB)
2. Nelson DR, Koymans L, Kamataki T, et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics. 1996;6:1–42
   • MEDLINE
3. Ding X, Kaminsky LS. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu. Rev. Pharmacol. Toxicol. 2003;43:149–173
   • MEDLINE
4. Chuang SS, Helvig C, Taimi M, et al. CYP2U1, a novel human thymus-and brain-specific cytochrome P450, catalyzes ω- and (ω−1)-hydroxylation of fatty acids. J. Biol. Chem. 2004;279:6305–6314
   • MEDLINE
5. Karlgren M, Backlund M, Johansson I, Oscarson M, Ingelman-Sundberg M. Characterization and tissue distribution of a novel human cytochrome P450-CYP2U1. Arch. Biochem. Biophys. 2004;315:679–685
6. Nelson DR, Zeldin DC, Hoffman S, Maltais LJ, Wain HM, Nebert DW. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics. 2004;14:1–18
   • MEDLINE
7. Karlgren M, Shin-ichi M, Ingelman-Sundberg M. Novel extrahepatic cytochrome P450s. Toxicol. Appl. Pharmacol. 2005;207:S57–S61
8. Bièche I, Narjoz C, Asselah T, et al. Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet. Genomics. 2007;17:731–742
9. Leclerc J, Tournel G, Courcot-Ngoubo Ngangue E, et al. JM profiling gene expression of whole cytochrome P450 superfamily in human bronchial and peripheral lung tissues: Differential expression in non-small cell lung cancers. Biochimie. 2010;92:292–306
10. Gebremedhin D, Lange AR, Lowry TF, et al. Production of 20-HETE and its role in autoregulation of cerebral blood flow. Circ. Res. 2000;87:60–65
    • MEDLINE
11. Miyata N, Roman RJ. Role of 20-hydroxyeicosatetraenoïc acid (20-HETE) in vascular system. J. Smooth Muscle Res. 2005;41:175–193
    • MEDLINE
12. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol. Rev. 2002;82:131–185
    • MEDLINE
13. Guengerich FP. Pharmacogenomics of cytochrome P450 and other enzymes involved in biotransformation of xenobiotics. Drug Dev. Res. 2000;49:4–16
14. Ingelman-Sundberg M. Polymorphism of cytochrome P450 and xenobiotic toxicity. Toxicology. 2002;181–182:447–452
15. Guengerich FP, Wu ZL, Bartleson CJ. Function of human cytochrome P450s: characterization of the orphans. Biochem. Biophys. Res. Commun. 2005;338:465–469
    • MEDLINE
16. Ingelman-Sundberg M. The human genome project and novel aspects of cytochrome P450 research. Toxicol. Appl. Pharmacol. 2005;207:52–56
    • MEDLINE
17. Cauffiez C. What have we learned from the novel human cytochromes P450 hidden in the databases?. Curr. Genomics. 2006;7:273–282
18. Hao CM, Breyer MD. Physiologic and pathophysiologic role of lipids mediators in the kidney?. Kidney Int. 2007;71:1105–1115
    • MEDLINE
19. Chaudhary KR, Batchu SN, Seubert JM. Cytochrome P450 enzymes and the heart. IUBMB Life. 2009;61:954–960
20. Powell PK, Wolf I, Jin R, Laskel JM. Metabolism of arachidonic acid to 20-hydroxy-5,8,11,14-eicosatetraenoic acid by P450 enzymes in human liver: involvement of CYP4F2 and CYP4A11. J. Pharmacol. Exp. Ther. 1998;285:1327–1336
    • MEDLINE
21. Lasker JM, Chen WB, Wolf I, Bloswick BP, Wilson PD, Powell PK. Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. Role of Cyp4F2 and Cyp4A11. J. Biol. Chem. 2000;275:4118–4126
    • MEDLINE
22. Gainer JV, Bellamine A, Dawson EP, et al. Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension. Circulation. 2005;111:63–69
23. Mayer B, Lieb W, Gotz A, et al. Association of the T8590C polymorphism of CYP4A11 with hypertension in the MONICA Augsburg echocardiographic substudy. Hypertension. 2005;46:766–771
24. Cauffiez C, Klinzig F, Rat E, et al. Functional characterization of genetic polymorphisms identified in the human cytochrome P450 4F12 (CYP4F12) promoter region. Biochem. Pharmacol. 2004;67:2231–2238
    • MEDLINE
25. Tournel G, Cauffiez C, Billaut-Laden I, et al. Molecular analysis of the CYP2F1 gene: identification of a frequent non-functional allelic variant. Mutat. Res. 2007;617:79–89
    • MEDLINE
26. Garat A, Cauffiez C, Hamdan-Khalil R, et al. IMPDH2 genetic polymorphism: a promoter single-nucleotide polymorphism disrupts a cyclic adenosine monophosphate responsive element. Genet. Test. Mol. Biomarkers. 2009;13:841–847
27. Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc. Natl. Acad. Sci. 1989;86:2766–2770
28. Hayashi K, Wandell DW. How sensitive is PCR-SSCP?. Human Mutat. 1993;5:73–79
29. Kumarakulasingham M, Rooney PH, Dundas SR, et al. Cytochrome p450 profile of colorectal cancer: identification of markers of prognosis. Clin. Cancer Res. 2005;11:3758–3765
    • MEDLINE
30. Downie D, McFadyen MC, Rooney PH, et al. Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers. Clin. Cancer Res. 2005;15:7369–7375
31. Marez D, Legrand M, Sabbagh N, et al. Genetic polymorphism of the human cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics. 1997;7:193–202
    • MEDLINE